HC Wainwright & Co. Maintains Buy on ArriVent BioPharma, Lowers Price Target to $27
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Robert Burns maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $47 to $27.
HC Wainwright & Co. analyst Robert Burns maintains ArriVent BioPharma (NASDAQ:AVBP) with a Buy and lowers the price target from $47 to $27.